1
|
Parillo F, Dall’Aglio C, Brecchia G, Maranesi M, Polisca A, Boiti C, Zerani M. Aglepristone (RU534) effects on luteal function of pseudopregnant rabbits: Steroid receptors, enzymatic activities, and hormone productions in corpus luteum and uterus. Anim Reprod Sci 2013; 138:118-32. [DOI: 10.1016/j.anireprosci.2013.02.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2012] [Revised: 01/31/2013] [Accepted: 02/07/2013] [Indexed: 11/30/2022]
|
2
|
Özalp GR, Çalışkan Ç, Seyrek-İntaş K, Wehrend A. Effects of the Progesterone Receptor Antagonist Aglepristone on Implantation Administered on Days 6 and 7 after Mating in Rabbits. Reprod Domest Anim 2008; 45:505-8. [DOI: 10.1111/j.1439-0531.2008.01282.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Özalp G, Seyrek-İntaş K, Çalışkan Ç, Wehrend A. Mid-gestation pregnancy termination in rabbits by the progesterone antagonist aglepristone. Theriogenology 2008; 69:1056-60. [DOI: 10.1016/j.theriogenology.2008.01.016] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2007] [Revised: 01/24/2008] [Accepted: 01/24/2008] [Indexed: 11/29/2022]
|
4
|
Ratnasooriya WD, Ratnayake SSK, Jayatunga YNA. Effects of Icon, a pyrethroid insecticide on early pregnancy of rats. Hum Exp Toxicol 2004; 22:523-33. [PMID: 14655718 DOI: 10.1191/0960327103ht381oa] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Icon is a water miscible type II synthetic pyrethroid insecticide based on active ingredient lambda cyhalothrin (10% w/w). It is used in Sri Lanka as an adulticidal indoor spray against malaria vector mosquitoes. The goal of this study was to assess the effects of Icon on pregnancy outcome of rats when exposed during early pregnancy (days 1-7). Icon was gavaged daily for 7 consecutive days in three different doses; 63, 83, or 125 mg/kg/day (active ingredient; lambda cyhalothrin; 6.3, 8.3, 12.5 mg/kg/day), respectively. Several parameters of reproduction and pre- and post-natal development were monitored. The results show that Icon is detrimental to pregnancy outcome (in terms of quantal pregnancy, number of uterine implants, implantation index and foetal deaths) but induced no detectable developmental defects. The anti-reproductive effects of Icon were mainly due to increased pre-implantation losses. Enhancement of post-implantation losses played a subsidiary role. These effects resulted from multiple mechanisms: maternal toxicity, stress, uterotropic activity and embryo-foetotoxicity. Further progesterone had a protective effect against Icon induced anti-reproductive actions. Overall, the results suggest that exposure to Icon during early gestation may result in a threat to pregnancy.
Collapse
Affiliation(s)
- W D Ratnasooriya
- Department of Zoology, University of Colombo, Colombo-3, Sri Lanka.
| | | | | |
Collapse
|
5
|
Weems YS, Bridges PJ, Sasser RG, Ching L, LeaMaster BR, Vincent DL, Weems CW. Effect of mifepristone on pregnancy, pregnancy-specific protein B (PSPB), progesterone, estradiol-17beta, prostaglandin F2alpha (PGF2alpha) and prostaglandin E (PGE) in ovariectomized 90-day pregnant ewes. Prostaglandins Other Lipid Mediat 2002; 70:195-208. [PMID: 12428689 DOI: 10.1016/s0090-6980(02)00110-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The objective of this experiment was to determine the effect of mifepristone, a progesterone receptor antagonist, on pregnancy and secretion of steroids, pregnancy-specific protein B (PSPB) and prostaglandins at mid-pregnancy in ewes. Ninety-day pregnant ewes were ovariectomized (OVX) and treatments were initiated 72 h post-OVX. Ewes received (1) vehicle, (2) prostaglandin F2alpha (PGF2alpha, 8 mg/58 kg/bw, i.m.) 84 h post-OVX, (3) mifepristone (50 mg intrajugular at 72, 84, 96, and 108 h post-OVX), (4) mifepristone (50mg) + PGF2alpha, (5) mifepristone (100 mg intrajugular at 72, 84, 96, and 108 h), and (6) mifepristone (100 mg) + PGF2alpha. Ewes treated with vehicle or PGF2alpha alone did not abort (P > or = 0.05). But, 60, 80, 60, and 100% of ewes treated with mifepristone (50 mg), mifepristone (50 mg) + PGF2alpha, mifepristone (100 mg), and mifepristone (100 mg) + PGF2alpha, respectively, aborted (P < or = 0.05). Profiles of progesterone, estradiol-17beta, prostaglandin E (PGE), or PSPB did not differ (P > or = 0.05) among treatment groups. Profiles of PGF2alpha of treatment groups receiving mifepristone with or without PGF2alpha differed (P < 0.05) from vehicle or PGF2alpha alone-treated ewes. It is concluded that progesterone actions are necessary to suppress uterine/placental secretion of PGF2alpha and that maintenance of critical progesterone: estradiol-17beta and PGE:PGF2alpha ratios are necessary for maintenance of pregnancy.
Collapse
Affiliation(s)
- Y S Weems
- Department of Human Nutrition, Food and Animal Sciences, University of Hawaii, Honolulu 96822, USA
| | | | | | | | | | | | | |
Collapse
|
6
|
Jimenez R, Yoburn BC, Calvano SE, Franklin SO. Preproenkephalin mRNA and enkephalin levels in the adult Syrian hamster: the influence from glucocorticoids. BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH 1999; 66:179-83. [PMID: 10095090 DOI: 10.1016/s0169-328x(99)00019-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Proenkephalin (Penk) gene structure in hamsters and humans are similar but they differ from rats. In this study hamster Penk gene expression was examined after hypophysectomy+/-glucocorticoid receptor blockade with RU 486 (mifepristone). In contrast to rats, basal Penk gene expression in hamster adrenals did not change after treatments that reduced both the influence from glucocorticoids and phenylethanolamine-N-methyltransferase mRNA levels. Meanwhile, striatal preproenkephalin mRNA levels increased under these conditions.
Collapse
Affiliation(s)
- R Jimenez
- Department of Pharmacology, Cornell University Medical College, 1300 York Avenue, New York, NY 10021, USA
| | | | | | | |
Collapse
|
7
|
Hafez B, Goff L, Hafez S. Recent advances in andrology research: physiopathology and clinical application to fertility and infertility. ARCHIVES OF ANDROLOGY 1997; 39:173-95. [PMID: 9352030 DOI: 10.3109/01485019708987916] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Sperm maturation depends on androgen and is mediated by several unidentified epididymal factors: glycoproteins and metabolites affecting acrosomal stability and fertilizing potential of capacitated sperm. Several genes encoding human epididymis-specific proteins have been described. One of the cloned epididymal cDNA encodes a polypeptide designated as HE4 with an estimated molecular mass of 10,000. Leydig cells are rich in lipid droplets and display epithelioid features. These cells have a cord-like arrangement; the cords are formed by one or two closely apposed cells. In between these cells, labyrinthine or canalicular-like spaces are opened in wide perivascular spaces that improve cell secretion of hormones and facilitate their transport into the blood, as well as the traffic of fluids and metabolites. Coagulation and liquefaction in human semen plays an important role in the capacitation of semen. The liquefaction of semen is retarded by the powerful synthetic inhibitors of 6-amidino-2-naphtyl-p-guanidinobenzoate dimethansulfonate.
Collapse
Affiliation(s)
- B Hafez
- Andrology Laboratory, Hafez/Hafez Reproductive Health Center, Kiawah Island, South Carolina 29455, USA
| | | | | |
Collapse
|
8
|
Li XJ, Yu H, Koide SS. Effect of mifepristone and antiestrogens on uterine PGF2 alpha and PGE2 concentrations in ovariectomized and pregnant rats. PROSTAGLANDINS 1997; 53:187-97. [PMID: 9206800 DOI: 10.1016/s0090-6980(97)00014-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Four antiestrogens (anordiol, tamoxifen, RU 39411, ICI 182780) and the antiprogestin, mifepristone (RU 486), were administered to the following three animal models: (1) ovariectomized rats, (2) mated rats treated post-coitally; and (3) pregnant rats treated post-implantation. The antiestrogens were administered alone or in combination with mifepristone at doses effective in preventing and/or terminating pregnancy in rats. The objective of the study was to determine whether these drugs influenced uterine concentrations of prostaglandins (PGF2 alpha and PGE2). Antiestrogens administered alone to ovariectomized rats did not effect uterine PGE2 or PGF2 alpha concentrations; whereas the combination of anordiol/mifepristone increased uterine PGF2 alpha concentration, resulting in an increase in the PGF2 alpha/PGE2 ratio. Mated rats were treated post-coitally for three consecutive days with anordiol, tamoxifen, estradiol and mifepristone alone and with the combination of anordiol/mifepristone and tamoxifen/mifepristone. An increase in uterine PGF2 alpha concentrations and in the PGF2 alpha/PGF2 ratio occurred only in anordiol/mifepristone treated group. A decrease in uterine PGE2 concentrations occurred in animals treated with anordiol, tamoxifen and estradiol, resulting in an increase in the PGF2 alpha/PGE2 ratio. Anordiol (5.0 mg/kg/day) and mifepristone (4.0 mg/kg/day) alone and the combination of anordiol/mifepristone (2.5/1.0 mg/kg/day) administered to pregnant rats on day 7, 8 and 9 of pregnancy induced an increase in PGF2 alpha levels without affecting uterine PGE2 concentration. The changes in PGF2 alpha concentrations induced by anordiol and the combination of anordiol/mifepristone resulted in an increase in the PGF2 alpha/PGE2 ratio. The antiestrogens tested except for ICI 182780 possessed agonist activity when assayed by measuring their capacity to increase the uterine weights in ovariectomized rats. Also, ICI 182789 was the only antiestrogen that did not influence uterine PG concentrations. It can be concluded that ICI 182780 is the only "pure" antiestrogen among those tested. The present results show that antiestrogens and the combination of mifepristone plus anordiol at doses preventing implantation and terminating pregnancy increase uterine PGF2 alpha and/or decrease PGE2 concentrations, resulting in an alteration of PGF2 alpha/PGE2 ratio. These findings suggest that there exists a critical balance of PGF2 alpha to PGE2 concentrations in the uterus required for the normal passage of fertilized ova through the oviduct, initiating implantation of the blastocysts, development of embryos, and maintenance of pregnancy.
Collapse
Affiliation(s)
- X J Li
- Department of Pharmacology, Beijing Medical University, China
| | | | | |
Collapse
|
9
|
Vanage GR, Dao B, Li XJ, Bardin CW, Koide SS. Effects of anordiol, an antiestrogen, on the reproductive organs of the male rat. ARCHIVES OF ANDROLOGY 1997; 38:13-21. [PMID: 9017118 DOI: 10.3109/01485019708988527] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Anordiol, an antiestrogen, was administered at doses of 2.5 and 10 mg/kg day-1 for 30 and 60 days to adult male rats. A significant decrease in serum LH, FSH, and testosterone levels occurred in the treated animals as compared to controls. Serum testosterone and LH levels decreased to about 15-35% of control value on day 15 of treatment and reached undetected levels thereafter. Serum FSH level also decreased to about 25-50% of control value by day 15 of treatment and remained at this level. Significant decrease in the weights of the tests and accessory reproductive organs occurred following anordiol treatment, while the body weights remained at pretreatment level. Histological examination of the tests revealed significant decrease in the diameter of the seminiferous tubules and in the number of germ cell elements. Spermatogenesis was arrested at the secondary spermatocyte stage. Leydig cells appeared atrophic and contained pyknotic nuclei. The epididymis, prostate, and seminal vesicle showed degenerative changes. The secretory activity of the glandular epithelium of the prostate gland appeared to be markedly reduced. In conclusion, anordiol acts by blocking gonadotropin production and/or release by the pituitary; thereby testosterone production by Leydig cells is not stimulated, causing spermatogenesis arrest.
Collapse
Affiliation(s)
- G R Vanage
- Institute for Research in Reproduction, Parel, Bombay, India
| | | | | | | | | |
Collapse
|
10
|
Dao B, Vanage G, Li XJ, Bardin CW, Koide SS. Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat. Contraception 1997; 55:35-40. [PMID: 9013059 DOI: 10.1016/s0010-7824(96)00239-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The effectiveness of mifepristone, onapristone, and ORG 31806 alone or in combination with anordiol to terminate pregnancy in the rat was evaluated. ORG 31806 at a dose of 2 mg/kg/day, mifepristone at 4 mg/kg/day, and onapristone at 8 mg/kg/day, terminated pregnancy in all treated animals. Anordiol, an antiestrogen, at a dose of 5 mg/kg/day, terminated pregnancy in all treated animals. Anordiol acted synergistically with all three antiprogestins terminating pregnancy in the rat. The antiprogestins at doses that were either partially effective or non-effective became 100% effective when administered with a non-effective dose of anordiol. Thus, combination of ORG 31806 (1 mg/kg/day) plus anordiol (0.31 mg/kg/ day), mifepristone (1 mg/kg/day) plus anordiol (0.62 mg/ kg/day), and onapristone (2 mg/kg/day) plus anordiol (2.5 mg/kg/day) terminated pregnancy in all treated animals. These combinations of the antiprogestins and anordiol decreased significantly the serum progesterone levels but not serum 17 beta-estradiol levels. The present results indicate that the most potent combination was ORG 31806 plus anordiol.
Collapse
Affiliation(s)
- B Dao
- Center for Biomedical Research, Population Council, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
11
|
Dao B, Vanage G, Marshall A, Bardin CW, Koide SS. Anti-implantation activity of antiestrogens and mifepristone. Contraception 1996; 54:253-8. [PMID: 8922879 DOI: 10.1016/s0010-7824(96)00196-5] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
To develop a better postcoital contraceptive, the following antiestrogens were tested for their anti-implantation activity in the rat: anordrin, anordiol, tamoxifen, ICI 182,780, and RU 39411. The compounds were administered orally or subcutaneously (s.c.) to female rats on days 1, 2, and 3 of pregnancy. All the antiestrogens tested were 100% effective in preventing blastocyst implantation. The lowest effective doses when administered orally were 10, 1.25, 0.062, 6.0 (partially effective), and 0.01 mg/kg/day, respectively. The estimated median effective doses (ED50) were 5.60, 0.40, 0.035, 5.40, and 0.0074 mg/kg/day, respectively. When administered s.c., the minimum effective doses in preventing blastocyst implantation in all animals were 2.0, 0.1, 0.1, 0.1, and 0.01 mg/kg/day, respectively. Anordrin, anordiol, and ICI 182,780 were more potent when administered s.c.; whereas tamoxifen and RU 39411 were effective at similar doses when administered parenterally or orally. RU 39411 was the most potent among the antiestrogens tested and should be evaluated as a potential postcoital contraceptive. The administration of mifepristone, an antiprogestin, at a dose of 8 mg/kg/day blocked blastocyst implantation in all treated animals; whereas at a dose of 4 mg/kg/day or lower, the drug was ineffective. These findings confirm that estradiol and progesterone are essential for blastocyst implantation in the rat. The capacity of mifepristone to potentiate the anti-implantation activity of the antiestrogens was also determined. The combination of a non-effective dose of each of the antiestrogens (anordrin, anordiol, and tamoxifen), and RU 39411, with mifepristone at a non-effective dose, prevented pregnancy, demonstration that an antiprogestin and antiestrogen act synergistically in blocking blastocyst implantation in the rat. The antiestrogen compounds whose anti-implantation activities were potentiated by mifepristone were found to possess significant estrogenic activity, when assayed by measuring the increase in the uterine weights of ovariectomized rats. The only exception was ICI 182,780, which showed no estrogenic activity in the uterine weight bioassay and did not act synergistically with mifepristone in blocking blastocyst implantation. Estradiol was effective in preventing pregnancy at a dose of 1 microgram/kg/day. The combination of non-effective doses of estradiol and mifepristone did not prevent pregnancy. The findings that mifepristone potentiates the anti-implantation activity suggests that the synergistic effect may be a unique property of this class of antiestrogens.
Collapse
Affiliation(s)
- B Dao
- Center for Biomedical Research, Population Council, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
12
|
Földesi I, Falkay G, Kovács L. Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study. Contraception 1996; 54:27-32. [PMID: 8804805 DOI: 10.1016/0010-7824(96)00116-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A human progesterone receptor assay has been developed for the measurement of the biologically active molecular fraction of RU486 (RU486 binding equivalent) for studying its pharmacokinetic properties. Thirty-nine healthy pregnant volunteers with amenorrhoea of 49 days or less receiving a single oral dose of 200 mg, 400 mg or 600 mg RU486 orally in a single dose were involved in this study. Blood samples were collected within 48 hours for the analysis. It was found that the pharmacokinetics of the RU486 binding equivalent followed an open two-compartment model. The dose was rapidly absorbed and peak serum concentrations were measured within 1-2 hours after ingestion of the drug. The distribution was also rapid, but the elimination was slow, the elimination half-life ranging between 83 and 90 hours. Significant differences were found between the peak plasma values for the 200 mg and 600 mg doses (p < 0.05) and between the AUCs for the 200 mg and 600 mg doses (p < 0.01) and the 400 mg and 600 mg doses (p < 0.05). It can be concluded that this newly developed radioreceptor assay satisfies the requirements of radioligand binding techniques and can be used to determine the serum levels of RU486 and its metabolites, which are able to bind to human myometrial progesterone receptors. The pharmacokinetics for the RU486 binding equivalent is similar to that for RU486, with the exception of very slow elimination, which may originate from the measurement of the biologically active metabolites together with the parent compound.
Collapse
Affiliation(s)
- I Földesi
- Department of Obstetrics and Gynaecology, WHO Collaborative Centre on Clinical Research in Human Reproduction, Szeged, Hungary
| | | | | |
Collapse
|
13
|
Juneja SC, Williams RS. Effect of anordrin on the development of mouse preimplantation embryos in vitro. J Assist Reprod Genet 1996; 13:356-62. [PMID: 8777353 DOI: 10.1007/bf02070152] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
PURPOSE The in vitro effect of anordrin and anordiol on the development of mouse two-cell embryos was studied. METHOD Female mice were primed with gonadotropins for superovulation and caged with male mice. Preimplantation embryos, at the two-cell stage, were recovered from the oviducts at 40 hr post-hCG. In the first experiment, two-cell embryos were exposed to culture medium containing different concentrations of anordrin for 3, 12, 24, and 80 hr and then grown in the anordrin-free culture medium and assessed for the formation of total and hatching blastocysts at 80 hr. In the second experiment, two-cell embryos were grown in culture medium containing different concentrations of anordiol and assessed for the formation of total and hatching blastocysts at 80 hr in vitro. RESULTS Exposure of two-cell embryos to anordrin concentrations of 2.5-7.5 micrograms/ml for 12 hr, 2.5-5.0 micrograms/ml for 24 hr, and 2.5 micrograms/ml for 80 hr caused significant inhibition of the formation of total blastocysts and to 2.5-7.5 micrograms/ml for 12 hr, 1.0-2.5 micrograms/ml for 24 hr, and 1.0 micrograms/ml for 80 hr caused significant inhibition of the formation of hatching blastocysts, in a exposure time-dependent and dose-dependent manner. Exposure of two-cell embryos to anordiol concentrations of 15-25 micrograms/ml for 80 hr caused significant inhibition of the formation of total blastocysts and to 15-20 micrograms/ml for 80 hr caused significant inhibition of the formation of hatching blastocysts in a dose-dependent manner. CONCLUSION Anordrin and its metabolite anordiol inhibit the development of two-cell embryos in vitro.
Collapse
|
14
|
Kaplan-Kraicer R, Bardin CW, Shalgi R. Anordiol and RU486 synergize to produce preimplantation pregnancy loss by increasing embryo transport (rat). Contraception 1995; 51:141-6. [PMID: 7750292 DOI: 10.1016/0010-7824(94)00020-w] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
RU486, an antiprogestational agent, and anordiol (dihydroxylated metabolite of anordrin) which has an estrogenic and antiestrogenic activity, are known to inhibit fertility. These agents were administered orally, alone or together, to rats prior to implantation, on Day 2 of pregnancy. Control animals were fed with the vehicle only. The effectiveness of the agents in terminating pregnancy in female rats was determined on Day 14 of pregnancy. Anordiol presented a dose-dependent effect on abolishing pregnancy, being 100% effective at 2.5 mg/Kg and non-effective at 0.6 mg/Kg. RU486 did not prevent pregnancy even at a dose of 4 mg/Kg. Doses of RU486 and anordiol that were ineffective when administered alone, prevented pregnancy in 70% of the rats when these agents were given together. To determine the mechanism by which these drugs prevent pregnancy, oviducts and uteri of rats were examined for presence of embryos on Day 3 of pregnancy. Only 29% of embryos were recovered from the oviducts of rats treated with 2.5 mg/Kg anordiol (compared to 89% in control group) plus an additional 9% from the uteri. In combination, anordiol and RU486 had a synergistic effect on embryo transport in the rats' reproductive tract, without any apparent accumulation in the uterus. These results led us to conclude that the pregnancy preventing action of anordiol plus RU486 is mostly due to accelerated transport of the embryos in the reproductive tract prior to implantation.
Collapse
Affiliation(s)
- R Kaplan-Kraicer
- Department of Embryology, Sackler School of Medicine, Tel Aviv University, Israel
| | | | | |
Collapse
|
15
|
Espey LL. Overview Oncologic, Endocrine & Metabolic: Female contraception: novel methods and developments. Expert Opin Ther Pat 1994. [DOI: 10.1517/13543776.4.6.629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
16
|
Wang WC, Chang CC, Bardin CW. Anordiol is more potent than anordrin for terminating pregnancy when administered with RU 486. Contraception 1993; 47:609-16. [PMID: 8334895 DOI: 10.1016/0010-7824(93)90028-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
In view of the unexpected ability of anordrin to synergize with RU 486 in terminating pregnancy, it was pertinent to examine the actions of the dihydroxylated metabolite of anordrin, anordiol, alone and in combination with RU 486. Does of RU 486 (1 mg/kg/day) and anordiol (0.6 mg/kg/day) that were ineffective when given alone terminated pregnancy with complete resorption of embryos when administered together. A smaller dose of anordiol than anordrin is required to achieve this synergistic effect with RU 486. This anordrin metabolite increased uterine weight in the ovariectomized rat similar to estradiol. The estrogenicity of anordiol in the uterine weight assay was about 1/120 of that of estradiol. Anordiol does not exert antiestrogenic activity in the uterine weight assay when administered at doses that terminate pregnancy. Administration of anordiol at doses that do not terminate pregnancy resulted in a significant suppression of serum progesterone concentrations during the period of medication; these observations suggest that anordiol has an inhibitory effect on progesterone biosynthesis. When the same dose of anordiol was given concomitantly with sufficient RU 486 (e.g., 1 mg/kg/day) to terminate pregnancy, the progesterone levels were reduced to low levels throughout the experiment. These observations support the postulate that the actions of anordrin are mediated by its metabolite, anordiol. The administration of anordiol plus RU 486 results in a more dramatic change in the functional progesterone:estradiol ratio than when either agent is administered alone.
Collapse
Affiliation(s)
- W C Wang
- Center for Biomedical Research, Population Council, New York, New York 10021
| | | | | |
Collapse
|
17
|
Vanage G, Kadam PA, Bardin CW, Koide SS. Potentiating effect of epostane on pregnancy terminating activity of RU 486 in the rat. Contraception 1993; 47:499-506. [PMID: 8513677 DOI: 10.1016/0010-7824(93)90102-d] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The effectiveness of a combination of RU 486, an antiprogestin, and epostane, a 3 beta-hydroxysteroid dehydrogenase inhibitor, for termination of pregnancy in female rats was determined. Epostane administered at doses ranging from 8 to 48 mg/Kg/day on days 7, 8, and 9 of pregnancy did not influence the progress of the pregnancy. RU 486 in doses of 1, 2, and 4 mg/Kg/day terminated pregnancy in 0, 40, and 100% of rats, respectively. The combination of epostane (48 mg/Kg/day) plus RU 486 (1 and 2 mg/Kg/day) terminated pregnancy with complete resorption of fetuses in all treated animals. Unexpectedly, the drug combination that terminated pregnancy used a dose of epostane that was not highly effective in lowering serum progesterone levels when epostane was administered alone. Thus, in the rat, the synergistic action of epostane plus RU 486 may not be dependent upon reduced progesterone secretion plus receptor blockage as anticipated. The present results suggest that the combination of epostane plus RU 486 is effective for pregnancy termination.
Collapse
Affiliation(s)
- G Vanage
- Center for Biomedical Research, Population Council, New York, NY 10021
| | | | | | | |
Collapse
|